Does This News From the FDA Make Eli Lilly a Buy for 2025?
Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...
US FDA says Lilly’s weight-loss drug shortage is resolved
The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster ...
FDA says Lilly weight loss drug shortage is over after taking a second look
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a ...
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
FDA approves generic in same class as Ozempic for diabetes. Could it ease shortage, price?
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...
Lilly obesity drug Mounjaro to be offered in Britain's NHS after watchdog nod
Eli Lilly's obesity drug Mounjaro will be available through Britain's state health system for some patients from March, after ...
FDA approves anti-obesity drug as first sleep apnea medication
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
FDA says knockoff versions of Lilly obesity drug must come off the market
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...
ABC News6 天
FDA: Knockoff versions of Lilly obesity drug must come off the market
The Food and Drug Administration said that a nationwide shortage of Eli Lilly’s Zepbound and Mounjaro ... obesity and Mounjaro is approved for diabetes. They use the same active ingredient ...
Eli Lilly’s Mounjaro Won’t Have Separate Sleep Apnea Label in EU
Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...
조선일보3 天
Keytruda maintains top sales in global drug market as diabetes drugs gain ground
Keytruda maintains top sales in global drug market as diabetes drugs gain ground Keytruda leads sales as metabolic disease ...